Studies of medications for addiction treatment in correctional settings cooperative (SOMATICS): Addressing the opioid crisis in vulnerable populations

David Farabee, UCLA Integrated Substance Abuse Programs, DFarabee@mednet.ucla.edu

Summary: With more than one in ten inmates in the US reporting regular opioid use, correctional settings offer an excellent opportunity for early identification and treatment of individuals with opioid use disorder (OUD). The importance of initiating treatment in jail is underscored by the fact that the risk of death during the first two weeks following release from prison is nearly 13 times greater than among individuals of similar demographic background, with drug overdose being the leading cause (Binswanger et al., 2007). But the use of medications to treat OUD remains inadequate in US correctional settings, placing persons with OUD at high risk for relapse to drug use, overdose, and mortality immediately following release from incarceration. The Studies on Medications for Addiction Treatment in Correctional Settings (SOMATICS) Collaborative, funded by the National Institute on Drug Abuse (NIDA), was designed to shed light on this critical public health problem. SOMATICS includes three research centers (RCs), each conducting an individual randomized trial while sharing the control condition study arm (Enhanced Treatment as Usual [ETAU]) as well as core assessments across all sites. Specifically, the trials compare (1) the initiation of medication (extended-release naltrexone (XR-NTX)–in New York City and in Albuquerque, NM and methadone in Baltimore, MD with vs. without patient navigation compared to ETAU for adult inmates with OUD who are transitioning to the community. This presentation will provide preliminary opioid use outcomes and cost data.

Key Words: extended release naltrexone, interim methadone, correctional, criminal justice

Are all Speakers Confirmed?: Yes

Have you proposed this same symposium to CPDD before?: No

Have you chaired a workshop or symposium at CPDD in the past 3 years?: Yes

Describe any special scheduling issues (e.g. foreign speaker can come to CPDD for only a limited time)?: None

Do you require AV equipment?: Yes

Would you accept a workshop?: Yes

IsaParentAbstract: 1

Prefix: Dr.

First Name: David

Last Name: Farabee

Degrees: MA MD Ph.D etc:: PhD
Email: DFarabee@mednet.ucla.edu

CC Email: DFarabee@mednet.ucla.edu

Company Affiliation: UCLA Integrated Substance Abuse Programs

Mailing Address: 11075 Santa Monica Blvd., Suite 100

City: Los Angeles

State: CA

Zip/Postal: 90025

Country: United States

Phone: 310.963.0009
SOMATICS research cooperative: The intersection between the justice system and the opioid epidemic

David Farabee, UCLA Integrated Substance Abuse Programs, DFarabee@mednet.ucla.edu

Is Speaker a CPDD Member?: No
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 1
Prefix: Dr.
First Name: David
Last Name: Farabee
Degrees: MA MD Ph.D etc.: PhD
Email: DFarabee@mednet.ucla.edu
CC Email: DFarabee@mednet.ucla.edu
Company Affiliation: UCLA Integrated Substance Abuse Programs
Mailing Address: 11075 Santa Monica Blvd., Suite 100
City: Los Angeles
State: CA
Zip/Postal: 90025
Country: United States
Phone: 310.963.0009
ID: 7

Opioid use disorder: Assessment, prevention, treatment relapse, and treatment retention

Francisco Salgado García, University of Tennessee Health Science Center, fsalgado@uthsc.edu

Chair: Francisco Salgado García

Co-Chair: Karen Derefinko

Summary: According to the 2016 National Survey on Drug Use and Health data, 11.8 million Americans over age 12 reported opioid medication misuse in the past month, demonstrating that opiate use is now a critical public health problem. Rates of misuse herald a rise in harms associated with opioid dependence; opioid overdose has tripled in 16 years and is responsible for 63% of drug overdose deaths. Prevention, treatment, and relapse prevention efforts are paramount to address the devastating effects of the opioid epidemic. The projects presented in this symposium reflect the importance of understanding the multifaceted problem of opioid use. First, because most clinicians rely on self-report and other limited ways to measure opioid use, we present pilot results of the feasibility of using wearable technology to detect self-administration of opioids in dental surgery patients. Second, we discuss results of a randomized controlled trial of a brief information session on appropriate opioid use for acute dental pain. Third, we examine the results from qualitative work assessing the factors of treatment retention in patients in opioid use disorder treatment are presented. Finally, we describe research examining the association between adverse childhood events (ACEs) and opioid relapse for patients in buprenorphine treatment.

Key Words: Opioid; misuse; biosensors; prevention; relapse

Are all Speakers Confirmed?: Yes

Have you proposed this same symposium to CPDD before?: No

Have you chaired a workshop or symposium at CPDD in the past 3 years?: No

Do you require AV equipment?: Yes

Would you accept a workshop?: No

IsaParentAbstract: 1

Prefix: Dr.

First Name: Francisco

Middle Initial: I

Last Name: Salgado García

Degrees: MA MD Ph.D etc:: Ph.D.
Email: fsalgado@uthsc.edu

Company Affiliation: University of Tennessee Health Science Center

Mailing Address: 66 N Pauline St

Address 2: Suite 617

City: Memphis

State: TN

Zip/Postal: 38163

Country: United States

Phone: 901 4483061
The use of wearable biosensors to track opioid self-administration in dental surgery patients

Francisco Salgado García, University of Tennessee Health Science Center, fsalgado@uthsc.edu

Is Speaker a CPDD Member?: No

Will this individual be the Discussant?: Yes

Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

First Name: Francisco
Middle Initial: I
Last Name: Salgado García
Degrees: MA MD Ph.D etc:: Ph.D.
Email: fsalgado@uthsc.edu
Company Affiliation: University of Tennessee Health Science Center
Mailing Address: 66 N Pauline St
Address 2: Suite 617
City: Memphis
State: TN
Zip/Postal: 38163
Country: United States
Phone: 901 4483061
The use of wearable biosensors to track opioid self-administration in dental surgery patients

Francisco Salgado García, University of Tennessee Health Science Center, fsalgado@uthsc.edu

Is Speaker a CPDD Member?: No
Will this individual be the Discussant?: Yes
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

First Name: Francisco
Middle Initial: I
Last Name: Salgado García
Degrees: MA MD Ph.D etc:: Ph.D.
Email: fsalgado@uthsc.edu
Company Affiliation: University of Tennessee Health Science Center
Mailing Address: 66 N Pauline St
Address 2: Suite 617
City: Memphis
State: TN
Zip/Postal: 38163
Country: United States
Phone: 901 4483061
A randomized trial of opioid misuse prevention in dental surgery patients

Francisco Salgado García, University of Tennessee Health Science Center, fsalgado@uthsc.edu

Is Speaker a CPDD Member?: No
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 7
Prefix: Dr.
First Name: Francisco
Middle Initial: I
Last Name: Salgado García
Degrees: MA MD Ph.D etc:: Ph.D.
Email: fsalgado@uthsc.edu

Company Affiliation: University of Tennessee Health Science Center

Mailing Address: 66 N Pauline St
Address 2: Suite 617
City: Memphis
State: TN
Zip/Postal: 38163
Country: United States
Phone: 901 4483061
ID: 11
Use of qualitative interviews to identify causes of buprenorphine-naloxone treatment discontinuation

Francisco Salgado García, University of Tennessee Health Science Center, fsalgado@uthsc.edu

Is Speaker a CPDD Member?: No
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 7
Prefix: Dr.
First Name: Francisco
Middle Initial: I
Last Name: Salgado García
Degrees: MA MD Ph.D etc:: Ph.D.
Email: fsalgado@uthsc.edu
Company Affiliation: University of Tennessee Health Science Center
Mailing Address: 66 N Pauline St
Address 2: Suite 617
City: Memphis
State: TN
Zip/Postal: 38163
Country: United States
Phone: 901 4483061
Adverse childhood experiences predict opioid treatment relapse in rural buprenorphine patients

Francisco Salgado García, University of Tennessee Health Science Center, fsalgado@uthsc.edu

Is Speaker a CPDD Member?: No

Will this individual be the Discussant?: No

Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0

ParentAbstract: 7

Prefix: Dr.

First Name: Francisco

Middle Initial: I

Last Name: Salgado García

Degrees: MA MD Ph.D etc:: Ph.D.

Email: fsalgado@uthsc.edu

Company Affiliation: University of Tennessee Health Science Center

Mailing Address: 66 N Pauline St

Address 2: Suite 617

City: Memphis

State: TN

Zip/Postal: 38163

Country: United States

Phone: 901 4483061
Self-sustaining strategies offering nondrug choices reduce long-term drug craving and relapse: Sex differences

Marilyn Carroll, University of Minnesota, mcarroll@umn.edu

Chair: Marilyn Carroll
Co-Chair: Wendy Lynch

Summary: Addiction to stimulant drugs such as nicotine, methamphetamine and cocaine cost millions of dollars to treat and still leads to millions of lives lost every year. This session explores the problem that after drug use stops through self-imposed abstinence or treatment craving begins incubates over weeks-months, and leads to relapse. This session will examine ways to treat “incubation of craving” and implement behavior change that can be self-maintained long after treatment ends. In animal studies this has been done by arranging for voluntary access to competing nondrug rewards that the user chooses in place of using drugs. In the four presentations 1) Venniro et al. show that rats will choose social interaction with another rat rather over methamphetamine or heroin, and this corresponds with activation of central amygdala AKCo expressing inhibitory neurons. 2) Carroll et al. discuss incubation of cocaine and nicotine craving in rats, and multi-triggered relapse that were blocked by voluntary aerobic exercise during a 4-week period when incubation of craving occurred. Sex differences in incubation of craving will be reported. 3) Lynch et al. will discuss aerobic exercise as an intervention cocaine relapse, as well as the importance of considering sex differences and molecular mechanisms in addiction and its treatment. 4) Silverman and Holtyn will discuss their human work with the therapeutic workplace as a model anti-poverty program to reduce addiction. A common theme is voluntary, self-maintained treatments over long durations to block incubation of craving and relapse.

Key Words: self-sustaining, treatments, long-term, reductions, incubation of craving, sex

Are all Speakers Confirmed?: Yes

Have you proposed this same symposium to CPDD before?: No

Have you chaired a workshop or symposium at CPDD in the past 3 years?: No

Describe any special scheduling issues (e.g. foreign speaker can come to CPDD for only a limited time)?: No

Do you require AV equipment?: Yes

Would you accept a workshop?: No

IsaParentAbstract: 1

Prefix: Dr.

First Name: Marilyn
Middle Initial: E.

Last Name: Carroll

Degrees: MA MD Ph.D etc:: Ph.D.

Email: mcarroll@umn.edu

Company Affiliation: University of Minnesota

Contact Title: Professor

Mailing Address: 505 Essex Street, S.E. Room 625-C Diehl Hall

City: Minneapolis

State: MN

Zip/Postal: 55455

Country: United States

Phone: (651) 398-1543

Fax: (612) 624-8935

Membership Year: 1993

Sponsor: J.V. Brady & A.E. Takemori

Research Interests: Behavioral Pharmacology, Molecular Biology, Pharmacology
Exploring non-opioid approaches for the treatment of pain

David Shurtleff, NCCIH/NIH, david.shurtleff@nih.gov

Chair: David Shurtleff
Co-Chair: Emmeline Edwards

Summary: Over 25 million Americans suffer from chronic pain, a highly debilitating medical condition that is complex and difficult to manage. In recent decades, there has been an overreliance on prescription opioids for chronic pain, contributing to an epidemic of opioid overdose deaths, misuse, addiction, and other harms, such as fractures and myocardial infarction. Evidence further indicates there is an associated dose-dependent risk for these harms. At the same time, there is insufficient evidence to determine the effectiveness of long-term opioid therapy for improving chronic pain and function. Given the risk-benefit profile of opioids for the management of pain, there is an increased interest in, and need for exploring, developing and utilizing non-opioid (including non-pharmacologic) approaches to manage pain. This symposium will explore some of these emerging interventions, and their underlying mechanisms as alternatives for the treatment of pain. Symposium topics will focus on the neuromodulatory effects of acupuncture and its role in pain management; the neuroimmune system’s role in modulating pain and analgesia, offering a novel target for medication development; the antinociceptive effects of green light therapy on chronic pain, highlighting possible mechanisms, and preliminary results from fibromyalgia and migraine clinical trials; and brain circuitry and neurochemistry associated with mindfulness-based meditation for the management of pain. Discussion will summarize key findings, and future directions including the NIH HEAL (Helping End Addiction Long-term) initiative goals in the discovery and pre-clinical development of pain treatments and advancing pain treatments through the clinical research pipeline.

Key Words: pain, treatment, neuroimmune, mindfulness, acupuncture

Are all Speakers Confirmed?: Yes

Have you proposed this same symposium to CPDD before?: No

Have you chaired a workshop or symposium at CPDD in the past 3 years?: No

Describe any special scheduling issues (e.g. foreign speaker can come to CPDD for only a limited time?)?: Dr. Napadow has limited availability, but could present on June 17 or 18.

Do you require AV equipment?: Yes

Would you accept a workshop?: No

IsaParentAbstract: 1

Prefix: Dr.

First Name: David
Last Name: Shurtleff

Degrees: MA MD Ph.D etc:: Ph.D

Email: david.shurtleff@nih.gov

Company Affiliation: NCCIH/NIH

Mailing Address: National Center for Complementary and Integrative Health (NCCIH)

Address 2: 31 Center Drive, Room 2B11

City: Bethesda

State: ND

Zip/Postal: 20892-6549

Country: United States

Phone: 301-435-6826

Fax: 301-435-6549
Achievement of sustained abstinence from drugs is currently the only valid endpoint accepted by the US Food and Drug Administration (FDA) for evaluating pharmacotherapies for most substance use disorders (alcohol use disorder being the exception). However, sustained abstinence is increasingly regarded as an overly stringent and restrictive outcome that may be a factor contributing to the shortage of approved pharmacotherapies. As part of the federal efforts to combat the opioid crisis, the FDA has recently expressed commitment to the development and use of new non-abstinence-based endpoints as part of product development. Yet despite long-standing interest and rising urgency, the identification of an alternative to sustained abstinence as a clinically meaningful endpoint for clinical trials has been elusive. This symposium will highlight the latest efforts and potential future directions toward the identification of meaningful non-abstinence based endpoints for various substances of abuse by leveraging data from completed clinical trials. This will include a presentation on novel, reduction-based endpoints for alcohol clinical trials, where is there precedent for regulators accepting outcomes other than abstinence (‘no heavy drinking days’) that may serve as a useful model for the development of alternative outcomes for other substances. Additional presentations in this symposium will review potential alternative endpoints in clinical trials for cocaine, cannabis, and opioids. The discussant will provide insight into the evolution of clinical trial endpoints and a vision for future directions.

Key Words: Clinical Trial Endpoints Clinically Meaningful Outcomes Substance Use Disorders

Are all Speakers Confirmed?: Yes

Have you proposed this same symposium to CPDD before?: No

Have you chaired a workshop or symposium at CPDD in the past 3 years?: No

Do you require AV equipment?: Yes

Would you accept a workshop?: No

IsaParentAbstract: 1

Prefix: Dr.

First Name: Brian

Middle Initial: D.

Last Name: Kiluk

Degrees: MA MD Ph.D etc:: Ph.D.
Email: brian.kiluk@yale.edu

Company Affiliation: Yale University School of Medicine

Contact Title: Associate Professor of Psychiatry

Mailing Address: 40 Temple St.

Address 2: Suite 6C

City: New Haven

State: CT

Zip/Postal: 06511

Country: United States

Phone: 2037373314

Membership Year: 2010

Sponsor: Dr. Katherine Carroll and Dr. Declan Barry

Travel Award: 2012

Research Interests: Behavioral Pharmacology, Treatment
Beyond abstinence: Reductions in drinking as an endpoint for alcohol clinical trials

Brian Kiluk, Yale University School of Medicine, brian.kiluk@yale.edu

Is Speaker a CPDD Member?: No
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

Prefix: Dr.
First Name: Brian
Middle Initial: D.
Last Name: Kiluk
Degrees: MA MD Ph.D etc.: Ph.D.
Email: brian.kiluk@yale.edu
Company Affiliation: Yale University School of Medicine
Contact Title: Associate Professor of Psychiatry
Mailing Address: 40 Temple St.
Address 2: Suite 6C
City: New Haven
State: CT
Zip/Postal: 06511
Country: United States
Phone: 2037373314
Membership Year: 2010
Sponsor: Dr. Katherine Carroll and Dr. Declan Barry
Travel Award: 2012

Research Interests: Behavioral Pharmacology, Treatment
ID: 17
Identifying meaningful alternatives to abstinence for cocaine use

Brian Kiluk, Yale University School of Medicine, brian.kiluk@yale.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes
IsaParentAbstract: 0
ParentAbstract: 15
Prefix: Dr.
First Name: Brian
Middle Initial: D.
Last Name: Kiluk
Degrees: MA MD Ph.D etc:: Ph.D.
Email: brian.kiluk@yale.edu
Company Affiliation: Yale University School of Medicine
Contact Title: Associate Professor of Psychiatry
Mailing Address: 40 Temple St.
Address 2: Suite 6C
City: New Haven
State: CT
Zip/Postal: 06511
Country: United States
Phone: 2037373314
Membership Year: 2010
Sponsor: Dr. Katherine Carroll and Dr. Declan Barry
Travel Award: 2012

Research Interests: Behavioral Pharmacology, Treatment
ID: 18
Cutting down on cannabis, can that be enough?

Brian Kiluk, Yale University School of Medicine, brian.kiluk@yale.edu

Is Speaker a CPDD Member?: Yes

Will this individual be the Discussant?: No

Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 15
Prefix: Dr.
First Name: Brian
Middle Initial: D.
Last Name: Kiluk
Degrees: MA MD Ph.D etc:: Ph.D.
Email: brian.kiluk@yale.edu

Company Affiliation: Yale University School of Medicine
Contact Title: Associate Professor of Psychiatry
Mailing Address: 40 Temple St.
Address 2: Suite 6C
City: New Haven
State: CT
Zip/Postal: 06511
Country: United States
Phone: 2037373314
Membership Year: 2010
Sponsor: Dr. Katherine Carroll and Dr. Declan Barry
**Travel Award:** 2012

**Research Interests:** Behavioral Pharmacology, Treatment
ID: 19
Reanalyzing opioid trials for non-abstinence-based endpoints

Brian Kiluk, Yale University School of Medicine, brian.kiluk@yale.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

ParentAbstract: 0
ParentAbstract: 15
Prefix: Dr.
First Name: Brian
Middle Initial: D.
Last Name: Kiluk
Degrees: MA MD Ph.D etc:: Ph.D.
Email: brian.kiluk@yale.edu
Company Affiliation: Yale University School of Medicine
Contact Title: Associate Professor of Psychiatry
Mailing Address: 40 Temple St.
Address 2: Suite 6C
City: New Haven
State: CT
Zip/Postal: 06511
Country: United States
Phone: 2037373314
Membership Year: 2010
Sponsor: Dr. Katherine Carroll and Dr. Declan Barry
Travel Award: 2012

Research Interests: Behavioral Pharmacology, Treatment
The point at the end: Where are we in the evolution of clinical trial endpoints, and where might we go?

Brian Kiluk, Yale University School of Medicine, brian.kiluk@yale.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: Yes
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 15
Prefix: Dr.
First Name: Brian
Middle Initial: D.
Last Name: Kiluk
Degrees: MA MD Ph.D etc:: Ph.D.
Email: brian.kiluk@yale.edu
Company Affiliation: Yale University School of Medicine
Contact Title: Associate Professor of Psychiatry
Mailing Address: 40 Temple St.
Address 2: Suite 6C
City: New Haven
State: CT
Zip/Postal: 06511
Country: United States
Phone: 2037373314
Membership Year: 2010
Sponsor: Dr. Katherine Carroll and Dr. Declan Barry
Travel Award: 2012

Research Interests: Behavioral Pharmacology, Treatment
ID: 21
Application of behavior analysis to the treatment of addiction: Reflections on a short career

Maxine Stitzer, Johns Hopkins Bayview Medical Center, mstitzer@jhmi.edu

Chair: Kathleen Carroll

Co-Chair: Maxine Stitzer

Summary: Nancy Petry was a creative and highly productive investigator who made many important contributions during a career cut short by her recent untimely death. This symposium is proposed in her honor to acknowledge and celebrate those many contributions. The title reflects the behavior analysis perspective that underpinned her work while the presentations highlight the major aspects of her contribution. In the first presentation, Warren Bickel will describe how Nancy began her career with work on behavioral economics and delay discounting, how that perspective informed her subsequent treatment development work and where the field has taken the early discounting work. John Roll will discuss Nancy’s creative contribution to the development and advance of contingency management as a treatment for substance use disorders and the large body of research she generated with her colleagues that has helped to cement this approach as an evidence-based treatment intervention. Carla Rash will follow with a discussion of Nancy’s substantial body of contingency management dissemination work, a valuable asset to clinicians. This work includes development of counselor training methods, research on efficacy of training interventions and dissemination of CM throughout the network of Veteran’s Administration substance use disorder programs. The fourth presentation by David Ledgerwood highlights another independent line of research on gambling disorders in which Nancy stimulated advances through her assessment and intervention research. The symposium will conclude with remarks by the session chairs. Overall, the symposium will provide a valuable review of Petry’s creative and productive career contributions while acknowledging her substantial impact.

Key Words: behavior analysis contingency management SUD treatment dissemination gambling

Are all Speakers Confirmed?: Yes

Have you proposed this same symposium to CPDD before?: No

Have you chaired a workshop or symposium at CPDD in the past 3 years?: No

Describe any special scheduling issues (e.g. foreign speaker can come to CPDD for only a limited time)?: none

Do you require AV equipment?: Yes

Would you accept a workshop?: Yes

IsaParentAbstract: 1

Prefix: Dr.
First Name: Maxine
Middle Initial: L.
Last Name: Stitzer
Degrees: MA MD Ph.D etc:: Ph.D.
Email: mstitzer@jhmi.edu
Company Affiliation: Johns Hopkins Bayview Medical Center
Contact Title: Professor of Psychiatry
Mailing Address: 5510 Nathan Shock Drive, Bldg. G, 3040
City: Baltimore
State: MD
Zip/Postal: 212246823
Country: United States
Phone: -4105500042
Fax: (410) 550-0030
Membership Year: 1992
Research Interests: Behavioral Pharmacology Treatment
Predictive modeling in addiction: Recent findings and implications for precision medicine

Sarah Yip, Yale University, sy356@nyu.edu

Chair: Sarah Yip

Co-Chair: Susan Whitfield-Gabrielli

Summary: Recent advances in predictive modeling and machine learning methods enable data-driven prediction of complex behaviors, including substance-use. By focusing on individual differences and generalization to novel subjects (i.e., cross-validation) these approaches overcome limitations of traditional approaches, increasing the likelihood of replication and potential translation to clinical settings. However, these methods are still relatively new to clinical research and have yet to be fully leveraged within the context of addictions. This symposium brings together junior and senior addiction researchers to demonstrate the potential of machine learning methods to inform clinical and neurobiological understanding of substance-use disorders and their treatment. Research will be presented to demonstrate the ability of these approaches to: (i) accurately classify substance-using versus non-substance-using individuals using resting state fMRI data; (ii) predict substance-use initiation in developmental cohorts; (iii) identify brain networks predictive of opioid and cocaine abstinence during treatment; and (iv) predict future relapse to methamphetamine. Presentations will cover findings from a range of machine learning approaches, including support vector regression, elastic net, and connectome-based predictive modeling approaches. The Discussant, a world-recognized expert in machine learning, will synthesize research findings and discuss implications for precision medicine. While the goal of this symposium is to showcase clinically relevant addiction findings derived from machine learning methods, our paired Workshop (‘Introduction to Machine Learning and Applications to Addiction Research’) will provide a practical introduction to machine learning methods to encourage future adoption of these methods in addiction research.

Key Words: brain-behavior modeling, machine learning, connectivity, treatment response, relapse

Are all Speakers Confirmed?: Yes

Have you proposed this same symposium to CPDD before?: No

Have you chaired a workshop or symposium at CPDD in the past 3 years?: Yes

Do you require AV equipment?: Yes

Would you accept a workshop?: No

IsaParentAbstract: 1

Prefix: Dr.

First Name: Sarah
Middle Initial: W.

Last Name: Yip

Degrees: MA MD Ph.D etc:: Ph.D.

Email: sy356@nyu.edu

Company Affiliation: Yale University

Mailing Address: 1 Church Street, 7th Floor, suite 731

City: New Haven

State: CT

Zip/Postal: 65103330

Country: United States

Phone: 2037047588

Fax: 203-737-4358

Membership Year: 2014

Sponsor: Dr, Kathleen Carroll, Ph.D. and Dr. Marc Potenza, MD, Ph.D.
ID: 23
Classifying and characterizing nicotine use disorder using support vector machine-based classification

Sarah Yip, Yale University, sy356@nyu.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 22

Prefix: Dr.
First Name: Sarah
Middle Initial: W.
Last Name: Yip

Degrees: MA MD Ph.D etc:: Ph.D.

Email: sy356@nyu.edu

Company Affiliation: Yale University

Mailing Address: 1 Church Street, 7th Floor, suite 731
City: New Haven
State: CT
Zip/Postal: 65103330
Country: United States
Phone: 2037047588
Fax: 203-737-4358

Membership Year: 2014

Sponsor: Dr, Kathleen Carroll, Ph.D. and Dr. Marc Potenza, MD, Ph.D.
Multi-modal, machine-learning methods for predicting substance use initiation

Sarah Yip, Yale University, sy356@nyu.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 22
Prefix: Dr.
First Name: Sarah
Middle Initial: W.
Last Name: Yip
Degrees: MA MD Ph.D etc:: Ph.D.
Email: sy356@nyu.edu
Company Affiliation: Yale University
Mailing Address: 1 Church Street, 7th Floor, suite 731
City: New Haven
State: CT
Zip/Postal: 65103330
Country: United States
Phone: 2037047588
Fax: 203-737-4358
Membership Year: 2014
Sponsor: Dr, Kathleen Carroll, Ph.D. and Dr. Marc Potenza, MD, Ph.D.
ID: 25
Connectome-based predictive modelling of polysubstance use in methadone maintained individuals

Sarah Yip, Yale University, sy356@nyu.edu

Is Speaker a CPDD Member?: No
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 22
Prefix: Dr.
First Name: Sarah
Middle Initial: W.
Last Name: Yip
Degrees: MA MD Ph.D etc:: Ph.D.
Email: sy356@nyu.edu
Company Affiliation: Yale University
Mailing Address: 1 Church Street, 7th Floor, suite 731
City: New Haven
State: CT
Zip/Postal: 65103330
Country: United States
Phone: 2037047588
Fax: 203-737-4358
Membership Year: 2014
Sponsor: Dr, Kathleen Carroll, Ph.D. and Dr. Marc Potenza, MD, Ph.D.
Bayesian computational adjustment of inhibitory control predicts relapse in methamphetamine dependence

Sarah Yip, Yale University, sy356@nyu.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

Prefix: Dr.
First Name: Sarah
Middle Initial: W.
Last Name: Yip
Degrees: MA MD Ph.D etc.: Ph.D.
Email: sy356@nyu.edu
Company Affiliation: Yale University
Mailing Address: 1 Church Street, 7th Floor, suite 731
City: New Haven
State: CT
Zip/Postal: 65103330
Country: United States
Phone: 2037047588
Fax: 203-737-4358
Membership Year: 2014
Sponsor: Dr, Kathleen Carroll, Ph.D. and Dr. Marc Potenza, MD, Ph.D.
ID: 27
Addiction prediction: Implications for precision medicine

Sarah Yip, Yale University, sy356@nyu.edu

Is Speaker a CPDD Member?: No
Will this individual be the Discussant?: Yes
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 22
Prefix: Dr.
First Name: Sarah
Middle Initial: W.
Last Name: Yip

Degrees: MA MD Ph.D etc:: Ph.D.

Email: sy356@nyu.edu
Company Affiliation: Yale University

Mailing Address: 1 Church Street, 7th Floor, suite 731
City: New Haven
State: CT
Zip/Postal: 65103330
Country: United States
Phone: 2037047588
Fax: 203-737-4358

Membership Year: 2014

Sponsor: Dr, Kathleen Carroll, Ph.D. and Dr. Marc Potenza, MD, Ph.D.
Stress and glucocorticoid effects in the prefrontal cortex: Implications for treatment of substance use disorders

Rajita Sinha, Yale University School of Medicine, rajita.sinha@yale.edu

Chair: Rajita Sinha

Co-Chair: Nicholas Goeders

Summary: Stress and drug use are intricately linked in substance use disorders (SUDs). However, the underlying pathophysiology is not well understood, and thus, treatment development efforts have lagged behind. In this translational symposium, speakers will present innovative and largely unpublished preclinical, translational and clinical research focused on the glucocorticoid and GABAergic mechanisms underlying stress and drug interactions, central glucocorticoid and neurosteroid effects on the prefrontal cortex and medications development to target this pathophysiology to reduce effects on drug craving, compulsive drug intake and relapse risk. Rajita Sinha will show evidence of stress and drug effects on peripheral and central glucocorticoid and prefrontal networks that may drive drug craving and intake in SUDs. John Mantsch will show that stress, via glucocorticoids can produce acute and persistent alterations within the mesocorticolimbic system that promote drug seeking. Nicholas Goeders will discuss central mechanisms of metyrapone and oxazepam, focusing on corticosterone and dopamine in the nucleus accumbens and prefrontal cortex to show that the combination reduces corticosterone in the medial prefrontal cortex to impact reduction in drug taking. Michael Detke will show medication development assessing the safety and initial efficacy of a combination drug (EMB-001; low-dose metyrapone + oxazepam) in targeting the stress response to improve clinical outcomes in cocaine and tobacco use disorders. Kathleen Brady will synthesize the presentations and discuss the mechanisms underlying stress, trauma and drug abuse as well as the need to identify potential biomarkers and novel treatments to enhance precision medicine in substance use disorders.

Key Words: Stress Glucocorticoids Prefrontal cortex Drug Intake GABA

Are all Speakers Confirmed?: Yes

Have you proposed this same symposium to CPDD before?: No

Have you chaired a workshop or symposium at CPDD in the past 3 years?: Yes

Describe any special scheduling issues (e.g. foreign speaker can come to CPDD for only a limited time)?: None

Do you require AV equipment?: No

Would you accept a workshop?: Yes

IsaParentAbstract: 1

Prefix: Dr.
First Name: Rajita

Last Name: Sinha

Degrees: MA MD Ph.D etc:: Ph.D.

Email: rajita.sinha@yale.edu

CC Email: julie.pinto@yale.edu

Company Affiliation: Yale University School of Medicine

Contact Title: Professor

Mailing Address: 2 Church Street South, Suite 209

City: New Haven

State: CT

Zip/Postal: 06519

Country: United States

Phone: 203-737-5805

Fax: 203-737-1272

Membership Year: 2002

Sponsor: Thomas R. Kosten, MD-Mary Jeanne Kreek, MD
Central and peripheral stress mechanisms underlying drug craving, intake and relapse risk

Rajita Sinha, Yale University School of Medicine, rajita.sinha@yale.edu

Is Speaker a CPDD Member?: Yes

Will this individual be the Discussant?: No

Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

Prefix: Dr.

First Name: Rajita

Last Name: Sinha

Degrees: MA MD Ph.D etc:: Ph.D.

Email: rajita.sinha@yale.edu

CC Email: julie.pinto@yale.edu

Company Affiliation: Yale University School of Medicine

Contact Title: Professor

Mailing Address: 2 Church Street South, Suite 209

City: New Haven

State: CT

Zip/Postal: 06519

Country: United States

Phone: 203-737-5805

Fax: 203-737-1272

Membership Year: 2002

Sponsor: Thomas R. Kosten, MD-Mary Jeanne Kreek, MD
Glucocorticoid-dependent regulation and dysregulation of the prefrontal cortex: Implications for relapse in substance use disorder populations

Rajita Sinha, Yale University School of Medicine, rajita.sinha@yale.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

Prefix: Dr.
First Name: Rajita
Last Name: Sinha
Degrees: MA MD Ph.D etc.: Ph.D.
Email: rajita.sinha@yale.edu
CC Email: julie.pinto@yale.edu
Company Affiliation: Yale University School of Medicine
Contact Title: Professor
Mailing Address: 2 Church Street South, Suite 209
City: New Haven
State: CT
Zip/Postal: 06519
Country: United States
Phone: 203-737-5805
Fax: 203-737-1272
Membership Year: 2002
Sponsor: Thomas R. Kosten, MD-Mary Jeanne Kreek, MD
ID: 32
Central mechanisms mediating the effects of metyrapone and oxazepam in rats

Rajita Sinha, Yale University School of Medicine, rajita.sinha@yale.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 29
Prefix: Dr.
First Name: Rajita
Last Name: Sinha
Degrees: MA MD Ph.D etc.: Ph.D.
Email: rajita.sinha@yale.edu
CC Email: julie.pinto@yale.edu
Company Affiliation: Yale University School of Medicine
Contact Title: Professor
Mailing Address: 2 Church Street South, Suite 209
City: New Haven
State: CT
Zip/Postal: 06519
Country: United States
Phone: 203-737-5805
Fax: 203-737-1272
Membership Year: 2002
Sponsor: Thomas R. Kosten, MD-Mary Jeanne Kreek, MD
Clinical safety and initial efficacy of combined metyrapone and oxazepam drug (EMB-001) in the treatment of cocaine and tobacco use disorders

Rajita Sinha, Yale University School of Medicine, rajita.sinha@yale.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 29
Prefix: Dr.
First Name: Rajita
Last Name: Sinha
Degrees: MA MD Ph.D etc:: Ph.D.
Email: rajita.sinha@yale.edu
CC Email: julie.pinto@yale.edu
Company Affiliation: Yale University School of Medicine
Contact Title: Professor
Mailing Address: 2 Church Street South, Suite 209
City: New Haven
State: CT
Zip/Postal: 06519
Country: United States
Phone: 203-737-5805
Fax: 203-737-1272
Membership Year: 2002
Sponsor: Thomas R. Kosten, MD-Mary Jeanne Kreek, MD
Stress mechanisms and implications for improving treatment outcomes in substance use disorders

Rajita Sinha, Yale University School of Medicine, rajita.sinha@yale.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: Yes
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 29
Prefix: Dr.
First Name: Rajita
Last Name: Sinha
Degrees: MA MD Ph.D etc:: Ph.D.
Email: rajita.sinha@yale.edu
CC Email: julie.pinto@yale.edu
Company Affiliation: Yale University School of Medicine
Contact Title: Professor
Mailing Address: 2 Church Street South, Suite 209
City: New Haven
State: CT
Zip/Postal: 06519
Country: United States
Phone: 203-737-5805
Fax: 203-737-1272
Membership Year: 2002
Sponsor: Thomas R. Kosten, MD-Mary Jeanne Kreek, MD
ID: 35
Brain imaging to assess neuroplasticity following acupuncture therapy for neuropathic pain

David Shurtleff, NCIHH/NIH, david.shurtleff@nih.gov

Is Speaker a CPDD Member?: No
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: No

IsaParentAbstract: 0
ParentAbstract: 14
Prefix: Dr.
First Name: David
Last Name: Shurtleff

Degrees: MA MD Ph.D etc.: Ph.D

Email: david.shurtleff@nih.gov

Company Affiliation: NCCIH/NIH
Mailing Address: National Center for Complementary and Integrative Health (NCCIH)
Address 2: 31 Center Drive, Room 2B11
City: Bethesda
State: ND
Zip/Postal: 20892-6549
Country: United States
Phone: 301-435-6826
Fax: 301-435-6549
Enhancement of opioid analgesia using chemokine receptor antagonists

David Shurtleff, NCCIH/NIH, david.shurtleff@nih.gov

Is Speaker a CPDD Member?: No

Will this individual be the Discussant?: No

Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0

ParentAbstract: 14

Prefix: Dr.

First Name: David

Last Name: Shurtleff

Degrees: MA MD Ph.D etc:: Ph.D

Email: david.shurtleff@nih.gov

Company Affiliation: NCCIH/NIH

Mailing Address: National Center for Complementary and Integrative Health (NCCIH)

Address 2: 31 Center Drive, Room 2B11

City: Bethesda

State: ND

Zip/Postal: 20892-6549

Country: United States

Phone: 301-435-6826

Fax: 301-435-6549
ID: 39
Discussant

David Shurtleff, NCCIH/NIH, david.shurtleff@nih.gov

Is Speaker a CPDD Member?: No

Will this individual be the Discussant?: Yes

Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

 IsaParentAbstract: 0

ParentAbstract: 14

Prefix: Dr.

First Name: David

Last Name: Shurtleff

Degrees: MA MD Ph.D etc:: Ph.D

Email: david.shurtleff@nih.gov

Company Affiliation: NCCIH/NIH

Mailing Address: National Center for Complementary and Integrative Health (NCCIH)

Address 2: 31 Center Drive, Room 2B11

City: Bethesda

State: ND

Zip/Postal: 20892-6549

Country: United States

Phone: 301-435-6826

Fax: 301-435-6549
ID: 40
fMRI biomarkers of drug cue reactivity for addiction medicine: From mechanisms to interventions

Hamed Ekhtiari, Laureate Institute for Brain Research, hekhtiari@laureateinstitute.org

Chair: Hamed Ekhtiari

Co-Chair: Amy Janes

Summary: Functional magnetic resonance imaging (fMRI) measures of neurobiological functions have revolutionized our understanding about mechanisms of drug addiction in humans. But, it is also true that fMRI does not yet have any role in the current daily clinical practice in addiction medicine. Drug cue reactivity paradigms are among the most commonly used approaches to record fMRI signals of interests that are assumed to be mechanistic mediators of clinical features that are key to managing persons with substance use disorders. Elements such as disease severity, treatment retention, relapse, and differential response to treatments and prognosis are often individualized, making the discovery of neurobiologic biomarkers even more germane. In this symposium, we will explore the methodological parameter space for fMRI measures of drug cue reactivity in different tasks/timing/analyses and will present new ideas for novel measures. We will also present ideas on how cue reactivity measures could be validated as predictive biomarkers for the clinical settings in addiction medicine. We will discuss how diverse settings for fMRI cue reactivity pioneered the field to explore a number of different potential biomarkers but meanwhile, made it hard to accumulate data across different labs to provide strong evidence for clinical use of these measures. Finally, we will incorporate the above insights and discuss how fMRI has facilitated a better understanding of the role that cue reactivity plays in addiction medicine in order to draw a roadmap for standardizing and validating fMRI cue reactivity biomarkers such that they can be employed into clinical practice.

Key Words: fMRI, Drug Cue, Biomarker, Addiction, Craving

Are all Speakers Confirmed?: Yes

Have you proposed this same symposium to CPDD before?: No

Have you chaired a workshop or symposium at CPDD in the past 3 years?: No

Describe any special scheduling issues (e.g. foreign speaker can come to CPDD for only a limited time)?: NA

Do you require AV equipment?: Yes

Would you accept a workshop?: No

IsaParentAbstract: 1

Prefix: Dr.

First Name: Hamed
Last Name: Ekhtiari

Degrees: MA MD Ph.D etc:: MD, PhD

Email: hekhtiari@laureateinstitute.org

CC Email: h.ekhtiari@gmail.com

Company Affiliation: Laureate Institute for Brain Research

Mailing Address: 4920 South Joplin Avenue

City: Tulsa

State: Oklahoma

Zip/Postal: 74135

Country: United States

Phone: 4059821656
From Pavlov to predictors: How cue reactivity fits into a comprehensive drug abuse prevention and treatment strategy

Hamed Ekhtiari, Laureate Institute for Brain Research, hekhtiari@laureateinstitute.org

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: Yes
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

Prefix: Dr.
First Name: Hamed
Last Name: Ekhtiari
Degrees: MA MD Ph.D etc.: MD, PhD
Email: hekhtiari@laureateinstitute.org
CC Email: h.ekhtiari@gmail.com
Company Affiliation: Laureate Institute for Brain Research
Mailing Address: 4920 South Joplin Avenue
City: Tulsa
State: Oklahoma
Zip/Postal: 74135
Country: United States
Phone: 4059821656
Outcomes of mindfulness based interventions in the treatment of maternal substance use

Diane Abatemarco, Thomas Jefferson University, diane.abatemarco@jefferson.edu

Chair: Diane Abatemarco
Co-Chair: Karol Kaltenbach

Summary: Maternal substance use and treatment is a complex public health concern. Women with substance use disorders report high levels of depression, anxiety, parenting stress, and adverse childhood exposures/trauma. Trauma as a leading cause for addiction behavior has not been systematically addressed. The use of mindfulness practices to ameliorate the effects of early life trauma and prevent intergenerational trauma among new mothers and their children have shown promise. Mindfulness practice supports mothers to be present with their children when interacting, while simultaneously highlighting non-judgment, self-compassion, self-regulation, and emotional awareness. This symposium will present data from two studies with women in treatment for opioid use disorder who participated in mindfulness-based interventions; one intervention during pregnancy and the other postnatally. The symposium will provide a comprehensive overview of the trauma informed intervention programs and how it each was designed to reduce stress, improve pregnancy outcomes and parenting responsiveness. A comprehensive presentation of the results will include both quantitative and qualitative findings. The quantitative data demonstrate improvement in general stress, parenting stress, mindfulness, parenting, and anxiety. The qualitative results focus on systematic program evaluation using focus groups and Re-AIM methods. Presentations will also include a comprehensive discussion of what the current research findings suggest for future mindfulness research in this population and the role of parenting to comprehensive treatment and relapse-prevention. Implications, plans for sustainability, and lessons learned including barriers and assets for including mindfulness in treatment programs for pregnant and parenting women with substance use disorders will also be discussed.

Key Words: mindfulness-based interventions maternal substance use treatment research evaluation maternal child health substance use and child health

Are all Speakers Confirmed?: Yes
Have you proposed this same symposium to CPDD before?: No
Have you chaired a workshop or symposium at CPDD in the past 3 years?: No
Do you require AV equipment?: Yes
Would you accept a workshop?: Yes

IsaParentAbstract: 1
Prefix: Dr.
First Name: Diane
Middle Initial: J.

Last Name: Abatemarco

Degrees: MA MD Ph.D etc:: Ph.D. M.S.W.

Email: diane.abatemarco@jefferson.edu

Company Affiliation: Thomas Jefferson University

Mailing Address: 1233 locust st

Address 2: suite 401

City: Philadelphia

State: PA

Zip/Postal: 10907

Country: United States

Phone: 6094604316
Overview of parenting quality and its relationship to comprehensive maternal substance use treatment

Diane Abatemarco, Thomas Jefferson University, diane.abatemarco@jefferson.edu

Is Speaker a CPDD Member?: Yes

Will this individual be the Discussant?: Yes

Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

Prefix: Dr.

First Name: Diane

Middle Initial: J.

Last Name: Abatemarco

Degrees: MA MD Ph.D etc:: Ph.D. M.S.W.

Email: diane.abatemarco@jefferson.edu

Company Affiliation: Thomas Jefferson University

Mailing Address: 1233 locust st

Address 2: suite 401

City: Philadelphia

State: PA

Zip/Postal: 10907

Country: United States

Phone: 6094604316
Reducing maternal stress and anxiety through mindfulness

Diane Abatemarco, Thomas Jefferson University, diane.abatemarco@jefferson.edu

Is Speaker a CPDD Member?: No
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes
IsaParentAbstract: 0
ParentAbstract: 46
Prefix: Dr.
First Name: Diane
Middle Initial: J.
Last Name: Abatemarco
Degrees: MA MD Ph.D etc:: Ph.D. M.S.W.
Email: diane.abatemarco@jefferson.edu
Company Affiliation: Thomas Jefferson University
Mailing Address: 1233 locust st
Address 2: suite 401
City: Philadelphia
State: PA
Zip/Postal: 10907
Country: United States
Phone: 6094604316
ID: 51
Predicting change in mindfulness-based outcomes: A multilevel modeling approach

Diane Abatemarco, Thomas Jefferson University, diane.abatemarco@jefferson.edu

Is Speaker a CPDD Member?: No
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 46
Prefix: Dr.
First Name: Diane
Middle Initial: J.
Last Name: Abatemarco

Degrees: MA MD Ph.D etc:: Ph.D. M.S.W.

Email: diane.abatemarco@jefferson.edu

Company Affiliation: Thomas Jefferson University

Mailing Address: 1233 locust st
Address 2: suite 401
City: Philadelphia
State: PA
Zip/Postal: 10907
Country: United States
Phone: 6094604316
Enlarging the toolbox: Using preclinical data to identify new targets for medication-assisted treatment of opioid use disorder

Jane Acri, National Institute on Drug Abuse, National Institutes of Health, jacri@nih.gov

Chair: Jane Acri
Co-Chair: Kurt Rasmussen

Summary: The CDC has reported that more than 42,000 Americans died of opioid overdose in 2016 and that over 2 million Americans live with opioid use disorder (OUD). In response to this public health crisis, the NIH has launched the HEAL (Helping to End Addiction Long-term) Initiative. Part of this initiative includes the development of new treatments for OUD to augment existing agonist/antagonist therapies. In this symposium, we will review preclinical data on several molecular targets that suggest their potential for the development of ligands as treatments for OUD. Dr. Kurt Rasmussen will then discuss how NIDA will help advance medication development efforts through interactions with the private sector, contract work, and new funding opportunities.

Key Words: targets, 5HT2c, D3, muscarinic M5, ghrelin

Are all Speakers Confirmed?: Yes
Have you proposed this same symposium to CPDD before?: No
Have you chaired a workshop or symposium at CPDD in the past 3 years?: Yes
Do you require AV equipment?: No
Would you accept a workshop?: No

Prefix: Dr.
First Name: Jane
Middle Initial: B.
Last Name: Acri

Degrees: MA MD Ph.D etc:: Ph.D.
Email: jacri@nih.gov

Company Affiliation: National Institute on Drug Abuse, National Institutes of Health

Mailing Address: 6001 Executive Boulevard, Rm 4123, MSC 9551
City: Bethesda

State: MD

Zip/Postal: 20892

Country: United States

Phone: (301) 827-5907

Fax: (301) 443-2599

Membership Year: 2005

Sponsor: Drs. Scott Lukas and Nancy Mello

Research Interests: Behavioral Pharmacology, Molecular Biology, Pharmacology
Discussant: NIDA as a catalyst for the development of new treatments for OUD

Jane Acri, National Institute on Drug Abuse, National Institutes of Health, jacri@nih.gov

Chair: Kurt Rasmussen

Is Speaker a CPDD Member?: No

Will this individual be the Discussant?: Yes

Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: No

IsaParentAbstract: 0

ParentAbstract: 52

Prefix: Dr.

First Name: Jane

Middle Initial: B.

Last Name: Acri

Degrees: MA MD Ph.D etc:: Ph.D.

Email: jacri@nih.gov

Company Affiliation: National Institute on Drug Abuse, National Institutes of Health

Mailing Address: 6001 Executive Boulevard, Rm 4123, MSC 9551

City: Bethesda

State: MD

Zip/Postal: 20892

Country: United States

Phone: (301) 827-5907

Fax: (301) 443-2599

Membership Year: 2005

Sponsor: Drs. Scott Lukas and Nancy Mello
Research Interests: Behavioral Pharmacology, Molecular Biology, Pharmacology
The implementation chasm for harm reduction services in rural areas

Hannah Cooper, Emory University, hcoope3@emory.edu

Chair: Hannah Cooper

Co-Chair: Rich Jenkins

Summary: Epicenters of opioid misuse and related harms have expanded from urban centers to rural areas. This expansion is creating wide “implementation chasms” for harm reduction services in rural areas; IOM defines “implementation chasms” as gaps between advances in scientific knowledge and their programmatic applications. Syringe service programs, for example, are vital harm reduction services, and yet 98% of young adults living in rural areas who tested positive for HCV in 2015/2016 had to travel >10 miles to reach such programs, compared with 46% of their urban counterparts. The symposium will present qualitative findings from four rural sites funded through the Rural Opioid Initiative, an initiative supported by NIDA, SAMHSA, the CDC, and the Appalachian Regional Commission. Presentations will illustrate the nature of this implementation chasm; identify novel strategies used in rural areas to close it; and describe opportunities to improve rural harm reduction systems. Specific topics include: - Implications of burgeoning methamphetamine co-use for the health of people who inject opioids and for harm reduction systems in rural Oregon. - The role of anti-MAT stigma in shaping access to and utilization of MAT among people who misuse opioids in the Ohio Valley - Opportunities for pharmacies to serve as harm reduction sites in Appalachian Kentucky - Experiences with overdose and Narcan among people who use opioids in 3 rural areas, and implications for harm reduction policy and practice. - The effect of siloed harm reduction organizations on the health of people who misuse opioids in the Ohio Valley

Key Words: Rural areas Opioid epidemic Harm reduction Implementation chasm Health equity

Are all Speakers Confirmed?: No

Have you proposed this same symposium to CPDD before?: No

Have you chaired a workshop or symposium at CPDD in the past 3 years?: No

Describe any special scheduling issues (e.g. foreign speaker can come to CPDD for only a limited time)?: N/A

Do you require AV equipment?: Yes

Would you accept a workshop?: No

IsaParentAbstract: 1

Prefix: Dr.

First Name: Hannah
Middle Initial: LF

Last Name: Cooper

Degrees: MA MD Ph.D etc:: ScD

Email: hcoope3@emory.edu

Company Affiliation: Emory University

Mailing Address: 1518 Clifton Road NE

City: Atlanta

State: GA

Zip/Postal: 30322

Country: United States

Phone: 3472779640
ID: 59
The dynamics of heroin: Changes in sources, forms and consequences

Jane Maxwell, Steve Hicks School of Social Work, jcmaxwell@sbcglobal.net

Chair: Jane Maxwell
Co-Chair: Phillip Coffin

Summary: The geographic source of the heroin available in the US drug market has transitioned several times over the last forty years. Each of the identified geographic source regions (Mexico, South America, Southeast Asia and Southwest Asia) has at one time or another been the dominant source of heroin available in the United States. Current DEA reporting indicates that Mexico is the primary source of origin for heroin transported to the United States. Highly refined and highly pure Mexican powder heroin now dominates the wholesale powder market. Heroin geo-source types can differ by purity, form, and processing method. The differing chemistries of these heroin type can lead to differing use patterns with attendant medical consequences. The areas of the U.S. most heavily affected by illicit fentanyl continue to be those parts of the country with high rates of powder heroin use. This symposium will feature presentations by DEA Fforestal chemists and intelligence analysts, as well as public health experts, who will discuss the transition in the different types of heroin available in the U.S., based on their studies on their epidemiological and ethnographic research on the East and West Coasts, the widespread and increasing availability of fentanyl, and the consequences of these changes. The objective of this symposia is to explore the under-recognized public health consequences of heroin use including overdose, soft tissue infection, HIV, and mortality. This symposium offers the opportunity to more closely examine the recent structural changes in the heroin market and their implications in the escalating heroin and fentanyl co-epidemics.

Key Words: heroin, fentanyl, Black Tar, public health

Are all Speakers Confirmed?: Yes

Have you proposed this same symposium to CPDD before?: No

Have you chaired a workshop or symposium at CPDD in the past 3 years?: No

Do you require AV equipment?: Yes

Would you accept a workshop?: No

Will this individual be the Discussant?: Yes

IsaParentAbstract: 1

Prefix: Dr.

First Name: Jane

Middle Initial: C
Last Name: Maxwell

Degrees: MA MD Ph.D etc:: Ph.D.

Email: jcmxwell@sbcglobal.net

CC Email: jcmxwell@mail.utexas.edu

Company Affiliation: Steve Hicks School of Social Work

Mailing Address: University of Texas at Austin

Address 2: 1717 West 6th

City: Austin

State: TX

Zip/Postal: 78703

Country: United States

Phone: 7044316534

Membership Year: 2003

Sponsor: Martin Iguchi-Michael Klein

Research Interests: Behavioral Pharmacology, Molecular Biology, Pharmacology
ID: 60
New findings in the Heroin Signature Program

Jane Maxwell, Steve Hicks School of Social Work, jcmaxwell@sbcglobal.net

Is Speaker a CPDD Member?: No
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 59
Prefix: Dr.
First Name: Jane
Middle Initial: C
Last Name: Maxwell
Degrees: MA MD Ph.D etc.: Ph.D.
Email: jcmaxwell@sbcglobal.net
CC Email: jcmaxwell@mail.utexas.edu
Company Affiliation: Steve Hicks School of Social Work
Mailing Address: University of Texas at Austin
Address 2: 1717 West 6th
City: Austin
State: TX
Zip/Postal: 78703
Country: United States
Phone: 7044316534
Membership Year: 2003
Sponsor: Martin Iguchi-Michael Klein
Research Interests: Behavioral Pharmacology, Molecular Biology, Pharmacology
From black tar to powder heroin markets in the U.S.: A review on heroin purity and cutting patterns

Jane Maxwell, Steve Hicks School of Social Work, jcmaxwell@sbcglobal.net

Is Speaker a CPDD Member?: No
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

First Name: Jane
Middle Initial: C
Last Name: Maxwell

Degrees: MA MD Ph.D etc.: Ph.D.

Email: jcmaxwell@sbcglobal.net
CC Email: jcmaxwell@mail.utexas.edu

Company Affiliation: Steve Hicks School of Social Work

Mailing Address: University of Texas at Austin

Address 2: 1717 West 6th
City: Austin
State: TX
Zip/Postal: 78703
Country: United States

Phone: 7044316534
Membership Year: 2003
Sponsor: Martin Iguchi-Michael Klein
Research Interests: Behavioral Pharmacology, Molecular Biology, Pharmacology
The dynamics of heroin: Changes in sources, forms and consequences

Jane Maxwell, Steve Hicks School of Social Work, jcmaxwell@sbcglobal.net

Is Speaker a CPDD Member?: Yes

Will this individual be the Discussant?: No

Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0

ParentAbstract: 59

Prefix: Dr.

First Name: Jane

Middle Initial: C

Last Name: Maxwell

Degrees: MA MD Ph.D etc.: Ph.D.

Email: jcmaxwell@sbcglobal.net

CC Email: jcmaxwell@mail.utexas.edu

Company Affiliation: Steve Hicks School of Social Work

Mailing Address: University of Texas at Austin

Address 2: 1717 West 6th

City: Austin

State: TX

Zip/Postal: 78703

Country: United States

Phone: 7044316534

Membership Year: 2003

Sponsor: Martin Iguchi-Michael Klein
Research Interests: Behavioral Pharmacology, Molecular Biology, Pharmacology
A triple event: Back-to-back-to-back opioid crises

Jane Maxwell, Steve Hicks School of Social Work, jcmaxwell@sbcglobal.net

Is Speaker a CPDD Member?: Yes

Will this individual be the Discussant?: No

Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0

ParentAbstract: 59

Prefix: Dr.

First Name: Jane

Middle Initial: C

Last Name: Maxwell

Degrees: MA MD Ph.D etc.: Ph.D.

Email: jcmaxwell@sbcglobal.net

CC Email: jcmaxwell@mail.utexas.edu

Company Affiliation: Steve Hicks School of Social Work

Mailing Address: University of Texas at Austin

Address 2: 1717 West 6th

City: Austin

State: TX

Zip/Postal: 78703

Country: United States

Phone: 7044316534

Membership Year: 2003

Sponsor: Martin Iguchi-Michael Klein
Research Interests: Behavioral Pharmacology, Molecular Biology, Pharmacology
What predicts early alcohol sipping, caffeine use, and screen media activity in youth? Two year findings from the Adolescent Brain Cognitive Development (ABCD) Study

Krista Lisdahl, University of Wisconsin-Milwaukee, krista.medina@gmail.com

Chair: Susan Weiss

Co-Chair: Krista Lisdahl

Summary: The Adolescent Brain Cognitive Development (ABCD) Study is a landmark multi-site 10-year longitudinal study that has now successfully enrolled over 11,800 youth. One aim of the ABCD Study is to examine the risk and protective factors influencing onset and trajectories of substance use (SU) outcomes. The current symposium will begin by presenting updated SU patterns observed in the ABCD youth at baseline and year-1 follow up (estimated n=11,800). For example, current baseline data (n=11,199) demonstrated approximately 23% of youth aged 9-10 reported sipping alcohol in their lifetime. By year 1, 12.6% of the 4508 participants to date reported a new onset of sipping alcohol. The speakers will then present a series of studies examining risk and resilience factors associated with early alcohol sipping, caffeine and screen media usage behaviors. Thus far, findings suggest that personality (e.g., impulsivity, sensation seeking, planning, perseverance, prosocial behavior), cognitive (problem solving), culture and environment (school involvement, parental religiosity, familism, family conflict), and demographics (gender, ethnicity) were linked with alcohol sipping. Youth with more general screen media usage demonstrated higher family conflict and more sleep disturbance. The symposium will include late-breaking findings (full cohort) and will discuss future directions and implications. On-going longitudinal assessment of these domains over a period of ten years in a diverse, nationwide sample of youth presents an exceptional opportunity to examine the factors influencing the onset and sequela of substance use and its consequences in youth that live in the United States.

Key Words: alcohol, caffeine, screen time, psychopathology, cognition

Are all Speakers Confirmed?: Yes

Have you proposed this same symposium to CPDD before?: No

Have you chaired a workshop or symposium at CPDD in the past 3 years?: No

Do you require AV equipment?: Yes

Would you accept a workshop?: Yes

IsaParentAbstract: 1

Prefix: Dr.

First Name: Krista

Middle Initial: M.
Last Name: Lisdahl

Degrees: MA MD Ph.D etc.: Ph.D.

Email: krista.medina@gmail.com

Company Affiliation: University of Wisconsin-Milwaukee

Mailing Address: 2441 East Hartford Ave

City: Milwaukee

State: WI

Zip/Postal: 53211

Country: United States

Phone: (414) 229-7159

Fax: (414) 2007229-5219

Membership Year: 2012

Sponsor: Dr. Susan Tapert and Dr. Alan Budney

Travel Award: 2007

Research Interests: Behavioral Pharmacology, Molecular Biology, Pharmacology
DISCUSSANT: Overview, implications, and discussion of year 2 findings from the ABCD Study

Krista Lisdahl, University of Wisconsin-Milwaukee, krista.medina@gmail.com

Is Speaker a CPDD Member?: No
Will this individual be the Discussant?: Yes
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: No

IsaParentAbstract: 0
ParentAbstract: 65
Prefix: Dr.
First Name: Krista
Middle Initial: M.
Last Name: Lisdahl
Degrees: MA MD Ph.D etc.: Ph.D.
Email: krista.medina@gmail.com
Company Affiliation: University of Wisconsin-Milwaukee
Mailing Address: 2441 East Hartford Ave
City: Milwaukee
State: WI
Zip/Postal: 53211
Country: United States
Phone: (414) 229-7159
Fax: (414) 2007229-5219
Membership Year: 2012
Sponsor: Dr. Susan Tapert and Dr. Alan Budney
Travel Award: 2007
Research Interests: Behavioral Pharmacology, Molecular Biology, Pharmacology
Mechanisms for sex and gender differences in addiction: Implications for prevention and treatment

Wendy Lynch, University of Virginia, wlynch@virginia.edu

Chair: Mark Smith

Co-Chair: Mariangela Martini

Summary: Sex and gender differences have been described for multiple aspects of addiction/substance use disorder including rates of use, vulnerability to use, progression to addiction, relapse, and treatment. In this session, we will explore recent evidence from human and laboratory animals for mechanisms underlying sex and gender differences in addiction focusing on biologically- and psychologically-based mechanisms. Mariangela Martini (North Caroline State University) will discuss evidence in mice for a role of sex chromosome complement in vulnerability to cocaine use as a mechanism underlying the enhanced vulnerability observed in females. Anousheh Bakhti-Suroosh (University of Virginia) will discuss evidence in rats for the enhancing effects of estradiol on the development of motivational aspects of an addicted phenotype as a mechanism underlying the enhanced progression to addiction observed in females. Mark Smith (Davidson College) will present data in rats showing that estradiol, which is known to enhance vulnerability to stimulants in females, has a different, and sometimes opposite effect, on sensitivity to opioids. Kathleen Brady (Medical University of South Carolina) will present data in humans on sex and gender differences in psychiatric comorbidities and will discuss how differences in the temporal relationship between the first presentation of addiction and the first psychiatric symptoms impact the trajectory of addiction. She will also present data on sex differences in response to stress and discuss implications for prevention and treatment. Finally, Marc Potenza (Yale University) will synthesize the findings from these various research perspectives with a view toward implications for sex/gender-specific prevention and treatment strategies.

Key Words: Addiction, Sex/Gender Differences, Substance Use Disorder, Mechanisms, Treatment

Are all Speakers Confirmed?: Yes

Have you proposed this same symposium to CPDD before?: No

Have you chaired a workshop or symposium at CPDD in the past 3 years?: No

Describe any special scheduling issues (e.g. foreign speaker can come to CPDD for only a limited time)?: None

Do you require AV equipment?: No

Would you accept a workshop?: No

IsaParentAbstract: 1

Prefix: Dr.
First Name: Wendy
Last Name: Lynch
Degrees: MA MD Ph.D etc.: Ph.D.
Email: wlynch@virginia.edu
Company Affiliation: University of Virginia
Contact Title: Associate Research Scientist
Mailing Address: 450 Ray C Hunt Dr
City: Charlottesville
State: VA
Zip/Postal: 22904
Country: United States
Phone: (434) 243-0580
Fax: (434) 973-7031
Membership Year: 2004
Sponsor: Marc Potenza M.D., Marilyn Carroll, Ph.D.
Research Interests: Behavioral Pharmacology, Molecular Biology, Pharmacology
Role of sex chromosome complement in vulnerability to cocaine use

Wendy Lynch, University of Virginia, wlynch@virginia.edu

Is Speaker a CPDD Member?: No
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

Prefix: Dr.
First Name: Wendy
Last Name: Lynch
Degrees: MA MD Ph.D etc:: Ph.D.
Email: wlynch@virginia.edu
Company Affiliation: University of Virginia
Contact Title: Associate Research Scientist
Mailing Address: 450 Ray C Hunt Dr
City: Charlottesville
State: VA
Zip/Postal: 22904
Country: United States
Phone: (434) 243-0580
Fax: (434) 973-7031
Membership Year: 2004
Sponsor: Marc Potenza M.D., Marilyn Carroll, Ph.D.
Research Interests: Behavioral Pharmacology, Molecular Biology, Pharmacology
Hormonal influences on the development of a cocaine addicted phenotype in females

Wendy Lynch, University of Virginia, wlynch@virginia.edu

Is Speaker a CPDD Member?: No
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: No

IsaParentAbstract: 0
ParentAbstract: 75
Prefix: Dr.
First Name: Wendy
Last Name: Lynch
Degrees: MA MD Ph.D etc.: Ph.D.
Email: wlynch@virginia.edu
Company Affiliation: University of Virginia
Contact Title: Associate Research Scientist
Mailing Address: 450 Ray C Hunt Dr
City: Charlottesville
State: VA
Zip/Postal: 22904
Country: United States
Phone: (434) 243-0580
Fax: (434) 973-7031
Membership Year: 2004
Sponsor: Marc Potenza M.D., Marilyn Carroll, Ph.D.
Research Interests: Behavioral Pharmacology, Molecular Biology, Pharmacology
ID: 78
Gonadal hormones and vulnerability to opioid use

Wendy Lynch, University of Virginia, wlynch@virginia.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 75
Prefix: Dr.
First Name: Wendy
Last Name: Lynch
Degrees: MA MD Ph.D etc:: Ph.D.
Email: wlynch@virginia.edu
Company Affiliation: University of Virginia
Contact Title: Associate Research Scientist
Mailing Address: 450 Ray C Hunt Dr
City: Charlottesville
State: VA
Zip/Postal: 22904
Country: United States
Phone: (434) 243-0580
Fax: (434) 973-7031
Membership Year: 2004
Sponsor: Marc Potenza M.D., Marilyn Carroll, Ph.D.
Research Interests: Behavioral Pharmacology, Molecular Biology, Pharmacology
ID: 79
Sex and gender differences in substance use disorder: Evidence from human studies

Wendy Lynch, University of Virginia, wlynch@virginia.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 75
Prefix: Dr.
First Name: Wendy
Last Name: Lynch
Degrees: MA MD Ph.D etc:: Ph.D.
Email: wlynch@virginia.edu
Company Affiliation: University of Virginia
Contact Title: Associate Research Scientist
Mailing Address: 450 Ray C Hunt Dr
City: Charlottesville
State: VA
Zip/Postal: 22904
Country: United States
Phone: (434) 243-0580
Fax: (434) 973-7031
Membership Year: 2004
Sponsor: Marc Potenza M.D., Marilyn Carroll, Ph.D.
Research Interests: Behavioral Pharmacology, Molecular Biology, Pharmacology
Sex/gender-specific prevention and treatment strategies for addiction

Wendy Lynch, University of Virginia, wlynch@virginia.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: Yes
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

Prefix: Dr.
First Name: Wendy
Last Name: Lynch
Degrees: MA MD Ph.D etc:: Ph.D.
Email: wlynch@virginia.edu
Company Affiliation: University of Virginia
Contact Title: Associate Research Scientist
Mailing Address: 450 Ray C Hunt Dr
City: Charlottesville
State: VA
Zip/Postal: 22904
Country: United States
Phone: (434) 243-0580
Fax: (434) 973-7031
Membership Year: 2004
Sponsor: Marc Potenza M.D., Marilyn Carroll, Ph.D.
Research Interests: Behavioral Pharmacology, Molecular Biology, Pharmacology
The abuse potential of medicinal cannabis products: Is this Mary Jane’s last dance?

Jermaine Jones, Columbia University College of Physicians and Surgeons, jonesje@nyspi.columbia.edu

Chair: Jermaine Jones

Co-Chair: Lauren Russell

Summary: As of September 2018, 31 states now offer access to legal medical marijuana products. In spite of Federal prohibition, current trends toward the legalization of cannabis products for medical use are underway despite limited data concerning their potential for non-medical use. The objective of this session, organized by the CPDD Committee on the Abuse Liability of Drugs, is to provide a review on what we know and do not know regarding abuse potential of medical cannabis products. This session will combine reviews of important abuse potential assessments with data-driven presentations on recent discoveries. First, Lauren Russell will describe differences between individuals who intend to use and do not intend to use medical cannabis once it becomes available in Arkansas, including medical diagnosis and prescription drug use within these populations. Second, Dr. Staci Gruber will provide general information on current medical cannabis patients, highlighting the relationship between use behavior and Cannabis Use Disorder Identification Test (CUDIT) assessment. Third, Dr. Ryan Vandrey will present data regarding novel behavioral and biological assessments of cannabis impairment. This presentation will include acute dose-effects of phytocannabinoid THC and the cannabis-derived terpene d-limonene alone and in combination. Fourth, Dr. Cinnamon Bidwell will provide an overview of the abuse liability of increasingly popular high-concentrate marijuana products. Lastly, Dr. Brenda Gannon will provide an overview of current medical cannabis concentrate regulations, including testing standards and how to formulate these products so they are less appealing to minors. Dr. Ryan Vandrey will serve as the discuant, providing a summary of the presentations.

Key Words: Abuse Potential Medicinal Cannabis Cannabinoids THC

Are all Speakers Confirmed?: Yes

Have you proposed this same symposium to CPDD before?: No

Have you chaired a workshop or symposium at CPDD in the past 3 years?: Yes

Do you require AV equipment?: Yes

Would you accept a workshop?: No

IsaParentAbstract: 1

Prefix: Dr.

First Name: Jermaine
Last Name: Jones

Email: jonesje@nyspi.columbia.edu

CC Email: jermainedjones@gmail.com

Company Affiliation: Columbia University College of Physicians and Surgeons

Mailing Address: 1051 Riverside Drive (Unit 120)

City: New York

State: NY

Zip/Postal: 10032

Country: United States

Phone: (646) 774-6113

Membership Year: 2010

Sponsor: Dr. Sandra Comer and Francis Levin

Travel Award: 2013

Research Interests: Behavioral Pharmacology

Date of Membership: 11.16.18 approved
ID: 82
The relationship between medicinal cannabis use behavior and cannabis use disorder

Jermaine Jones, Columbia University College of Physicians and Surgeons, jonesje@nyspi.columbia.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 81
Prefix: Dr.
First Name: Jermaine
Last Name: Jones
Email: jonesje@nyspi.columbia.edu
CC Email: jermainedjones@gmail.com
Company Affiliation: Columbia University College of Physicians and Surgeons
Mailing Address: 1051 Riverside Drive (Unit 120)
City: New York
State: NY
Zip/Postal: 10032
Country: United States
Phone: (646) 774-6113
Membership Year: 2010
Sponsor: Dr. Sandra Comer and Francis Levin
Travel Award: 2013
Research Interests: Behavioral Pharmacology
Date of Membership: 11.16.18 approved
ID: 83
Trauma, PTSD, and opioid addiction

Christal Badour, University of Kentucky, Christal.badour@uky.edu

Chair: Christal Badour
Co-Chair: Sudie Back

Summary: Trauma exposure and posttraumatic stress disorder (PTSD) are highly prevalent among individuals with opioid use disorder (OUD), and each are independently associated with poorer treatment outcomes. Despite these links, there is a dearth of research examining the specific nature of relations between opioid addiction and both trauma exposure and PTSD. In the current symposium, Dr. Christal Badour will present event-level data examining how daily variability in PTSD symptoms and motives for use prospectively predict non-medical use of prescription opioids. Dr. Jessica Peirce will consider risk factors for traumatic re-exposure among OUD patients engaging in medication-assisted treatment (MAT). Dr. Angela Moreland will present data examining rates of interpersonal violence, PTSD, and depression among women receiving MAT and will discuss past and current engagement in trauma-specific mental health treatment. Dr. Amanda Gilmore will present treatment outcome data from veterans with PTSD-OUD versus PTSD-other substance use disorders receiving COPE (Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure), an integrated treatment for dual diagnosis patients. Finally, Dr. Sudie Back will serve as discussant to review how these presentations fit with the broader context of OUD diagnosis and treatment and lead a discussion regarding future directions for research in this area.

Key Words: Opioids; Posttraumatic Stress, PTSD, Trauma

Are all Speakers Confirmed?: Yes

Have you proposed this same symposium to CPDD before?: No

Have you chaired a workshop or symposium at CPDD in the past 3 years?: No

Do you require AV equipment?: Yes

Would you accept a workshop?: Yes

IsaParentAbstract: 1

Prefix: Dr.

First Name: Christal
Last Name: Badour
Email: Christal.badour@uky.edu

Company Affiliation: University of Kentucky
Mailing Address: 207-N Kastle Hall

Address 2: University of Kentucky

City: Lexington

State: KY

Zip/Postal: 40506

Country: United States

Phone: 18593233817
ID: 84
Characterization of individuals who intend to use medical cannabis in Arkansas

Jermaine Jones, Columbia University College of Physicians and Surgeons, jonesje@nyspi.columbia.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 81
Prefix: Dr.
First Name: Jermaine
Last Name: Jones
Email: jonesje@nyspi.columbia.edu
CC Email: jermainedjones@gmail.com

Company Affiliation: Columbia University College of Physicians and Surgeons
Mailing Address: 1051 Riverside Drive (Unit 120)
City: New York
State: NY
Zip/Postal: 10032
Country: United States
Phone: (646) 774-6113
Membership Year: 2010
Sponsor: Dr. Sandra Comer and Francis Levin
Travel Award: 2013
Research Interests: Behavioral Pharmacology
Date of Membership: 11.16.18 approved
Novel behavioral and biological assessments of cannabis impairment

Jermaine Jones, Columbia University College of Physicians and Surgeons, jonesje@nyspi.columbia.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: Yes
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 81
Prefix: Dr.
First Name: Jermaine
Last Name: Jones
Email: jonesje@nyspi.columbia.edu
CC Email: jermainedjones@gmail.com
Company Affiliation: Columbia University College of Physicians and Surgeons
Mailing Address: 1051 Riverside Drive (Unit 120)
City: New York
State: NY
Zip/Postal: 10032
Country: United States
Phone: (646) 774-6113
Membership Year: 2010
Sponsor: Dr. Sandra Comer and Francis Levin
Travel Award: 2013
Research Interests: Behavioral Pharmacology
Date of Membership: 11.16.18 approved
An overview of current medical cannabis regulations and testing standards

Jermaine Jones, Columbia University College of Physicians and Surgeons,
jonesje@nyspi.columbia.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

Prefix: Dr.
First Name: Jermaine
Last Name: Jones
Email: jonesje@nyspi.columbia.edu
CC Email: jermainedjones@gmail.com

Company Affiliation: Columbia University College of Physicians and Surgeons
Mailing Address: 1051 Riverside Drive (Unit 120)
City: New York
State: NY
Zip/Postal: 10032
Country: United States
Phone: (646) 774-6113
Membership Year: 2010
Sponsor: Dr. Sandra Comer and Francis Levin
Travel Award: 2013
Research Interests: Behavioral Pharmacology
Date of Membership: 11.16.18 approved
ID: 87
The abuse liability of high-concentrate marijuana

Jermaine Jones, Columbia University College of Physicians and Surgeons,
jonesje@nyspi.columbia.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 81
Prefix: Dr.
First Name: Jermaine
Last Name: Jones
Email: jonesje@nyspi.columbia.edu
CC Email: jermainedjones@gmail.com
Company Affiliation: Columbia University College of Physicians and Surgeons
Mailing Address: 1051 Riverside Drive (Unit 120)
City: New York
State: NY
Zip/Postal: 10032
Country: United States
Phone: (646) 774-6113
Membership Year: 2010
Sponsor: Dr. Sandra Comer and Francis Levin
Travel Award: 2013
Research Interests: Behavioral Pharmacology
Date of Membership: 11.16.18 approved
ID: 88
Daily experiences of posttraumatic stress and non-medical prescription opioid use

Christal Badour, University of Kentucky, Christal.badour@uky.edu

Is Speaker a CPDD Member?: No
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 83
Prefix: Dr.
First Name: Christal
Last Name: Badour
Email: Christal.badour@uky.edu
Company Affiliation: University of Kentucky
Mailing Address: 207-N Kastle Hall
Address 2: University of Kentucky
City: Lexington
State: KY
Zip/Postal: 40506
Country: United States
Phone: 18593233817
ID: 89
Risk for traumatic event re-exposure during medication-assisted treatment

Christal Badour, University of Kentucky, Christal.badour@uky.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 83
Prefix: Dr.
First Name: Christal
Last Name: Badour
Email: Christal.badour@uky.edu
Company Affiliation: University of Kentucky
Mailing Address: 207-N Kastle Hall
Address 2: University of Kentucky
City: Lexington
State: KY
Zip/Postal: 40506
Country: United States
Phone: 18593233817
Concurrent treatment of PTSD and substance use disorders using prolonged exposure (COPE) for individuals with prescription opioid use disorder: A pilot study

Christal Badour, University of Kentucky, Christal.badour@uky.edu

Is Speaker a CPDD Member?: No

Will this individual be the Discussant?: No

Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0

ParentAbstract: 83

Prefix: Dr.

First Name: Christal

Last Name: Badour

Email: Christal.badour@uky.edu

Company Affiliation: University of Kentucky

Mailing Address: 207-N Kastle Hall

Address 2: University of Kentucky

City: Lexington

State: KY

Zip/Postal: 40506

Country: United States

Phone: 18593233817
ID: 92
Discussant

Christal Badour, University of Kentucky, Christal.badour@uky.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: Yes
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 83
Prefix: Dr.
First Name: Christal
Last Name: Badour
Email: Christal.badour@uky.edu
Company Affiliation: University of Kentucky
Mailing Address: 207-N Kastle Hall
Address 2: University of Kentucky
City: Lexington
State: KY
Zip/Postal: 40506
Country: United States
Phone: 18593233817
Marilyn Carroll, University of Minnesota, mcarroll@umn.edu

Is Speaker a CPDD Member?: No

Will this individual be the Discussant?: No

Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0

Prefix: Dr.

First Name: Marilyn

Middle Initial: E.

Last Name: Carroll

Degrees: MA MD Ph.D etc.: Ph.D.

Email: mcarroll@umn.edu

Company Affiliation: University of Minnesota

Contact Title: Professor

Mailing Address: 505 Essex Street, S.E. Room 625-C Diehl Hall

City: Minneapolis

State: MN

Zip/Postal: 55455

Country: United States

Phone: (651) 398-1543

Fax: (612) 624-8935

Membership Year: 1993

Sponsor: J.V. Brady & A.E. Takemori

Research Interests: Behavioral Pharmacology, Molecular Biology, Pharmacology
Operant social interaction inhibits drug self-administration and incubation of drug craving in rat addiction models

Marilyn Carroll, University of Minnesota, mcarroll@umn.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

Prefix: Dr.
First Name: Marilyn
Middle Initial: E.
Last Name: Carroll
Degrees: MA MD Ph.D etc.: Ph.D.
Email: mcarroll@umn.edu

Company Affiliation: University of Minnesota
Contact Title: Professor
Mailing Address: 505 Essex Street, S.E. Room 625-C Diehl Hall
City: Minneapolis
State: MN
Zip/Postal: 55455
Country: United States
Phone: (651) 398-1543
Fax: (612) 624-8935
Membership Year: 1993
Sponsor: J.V. Brady & A.E. Takemori
**Research Interests:** Behavioral Pharmacology, Molecular Biology, Pharmacology
Voluntary aerobic exercise reduces incubation of cocaine and nicotine craving and multi-triggered relapse in rats: Sex differences

Marilyn Carroll, University of Minnesota, mcarroll@umn.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 13
Prefix: Dr.
First Name: Marilyn
Middle Initial: E.
Last Name: Carroll
Degrees: MA MD Ph.D etc.: Ph.D.
Email: mcarroll@umn.edu
Company Affiliation: University of Minnesota
Contact Title: Professor
Mailing Address: 505 Essex Street, S.E. Room 625-C Diehl Hall
City: Minneapolis
State: MN
Zip/Postal: 55455
Country: United States
Phone: (651) 398-1543
Fax: (612) 624-8935
Membership Year: 1993
Sponsor: J.V. Brady & A.E. Takemori
Research Interests: Behavioral Pharmacology, Molecular Biology, Pharmacology
Voluntary aerobic exercise as an intervention for cocaine relapse: Sex differences and molecular mechanisms

Marilyn Carroll, University of Minnesota, mcarroll@umn.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 13
Prefix: Dr.
First Name: Marilyn
Middle Initial: E.
Last Name: Carroll
Degrees: MA MD Ph.D etc:: Ph.D.
Email: mcarroll@umn.edu
Company Affiliation: University of Minnesota
Contact Title: Professor
Mailing Address: 505 Essex Street, S.E. Room 625-C Diehl Hall
City: Minneapolis
State: MN
Zip/Postal: 55455
Country: United States
Phone: (651) 398-1543
Fax: (612) 624-8935
Membership Year: 1993
Sponsor: J.V. Brady & A.E. Takemori
Research Interests: Behavioral Pharmacology, Molecular Biology, Pharmacology
Employment-based incentives to address interrelated problems of poverty and drug addiction

Marilyn Carroll, University of Minnesota, mcarroll@umn.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

First Name: Marilyn
Middle Initial: E.
Last Name: Carroll
Degrees: MA MD Ph.D etc.: Ph.D.
Email: mcarroll@umn.edu
Company Affiliation: University of Minnesota
Contact Title: Professor
Mailing Address: 505 Essex Street, S.E. Room 625-C Diehl Hall
City: Minneapolis
State: MN
Zip/Postal: 55455
Country: United States
Phone: (651) 398-1543
Fax: (612) 624-8935
Membership Year: 1993
Sponsor: J.V. Brady & A.E. Takemori
Research Interests: Behavioral Pharmacology, Molecular Biology, Pharmacology
Where do these models need to go to make a quantum leap in treating drug addiction?

Marilyn Carroll, University of Minnesota, mcarroll@umn.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: Yes
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

First Name: Marilyn
Middle Initial: E.
Last Name: Carroll
Degrees: MA MD Ph.D etc:: Ph.D.
Email: mcarroll@umn.edu
Company Affiliation: University of Minnesota
Contact Title: Professor
Mailing Address: 505 Essex Street, S.E. Room 625-C Diehl Hall
City: Minneapolis
State: MN
Zip/Postal: 55455
Country: United States
Phone: (651) 398-1543
Fax: (612) 624-8935
Membership Year: 1993
Sponsor: J.V. Brady & A.E. Takemori
Research Interests: Behavioral Pharmacology, Molecular Biology, Pharmacology
ID: 99
Discussant

Jane Maxwell, Steve Hicks School of Social Work, jcmaxwell@sbcglobal.net

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: Yes
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 59
Prefix: Dr.
First Name: Jane
Middle Initial: C
Last Name: Maxwell
Degrees: MA MD Ph.D etc:: Ph.D.
Email: jcmaxwell@sbcglobal.net
CC Email: jcmaxwell@mail.utexas.edu
Company Affiliation: Steve Hicks School of Social Work
Mailing Address: University of Texas at Austin
Address 2: 1717 West 6th
City: Austin
State: TX
Zip/Postal: 78703
Country: United States
Phone: 7044316534
Membership Year: 2003
Sponsor: Martin Iguchi-Michael Klein
Research Interests: Behavioral Pharmacology, Molecular Biology, Pharmacology
To smoke or not to smoke: That is the cue-estion

Yasmin Zakiniaeiz, Yale University, yasmin.zakiniaeiz@yale.edu

Chair: Yasmin Zakiniaeiz
Co-Chair: Eric Woodcock

Summary: Cue-reactivity, physiological and/or subjective responses to drug-related stimuli, plays a critical role in maintaining drug use and precipitating relapse. Neuroimaging research has highlighted important neural structures and circuits that mediate physiological and subjective responses to cigarette-related cues, which have been linked to continued drug use. This symposium will showcase human neuroimaging and laboratory work to explore the specific brain regions involved in cue reactivity as well as the influence of (1) acute stress, (2) biological sex/hormones, and (3) novel interventions, on cue-reactivity and smoking behavior in cigarette smokers. Insight into factors that influence cue-reactivity are likely to provide new targets for smoking cessation. Novel interventions such as using nicotine-free electronic cigarettes as adjuvant therapy, timing quit dates to coincide with hormonal variation, and reconsolidation-based strategies will be discussed. The Speakers, leaders in the field of cigarette smoking cue-reactivity, will present neuroimaging and behavioral findings that highlight the importance of cue-reactivity from drug craving to drug seeking to treatment outcomes. The Discussant, an expert in neuroimaging stress and cue-reactivity of addictive disorders, will synthesize study findings and identify knowledge gaps to facilitate audience discussion on the challenges and opportunities of cue-reactivity in smokers.

Key Words: Cigarette smoking, cue-reactivity, stress, sex, neuroimaging

Are all Speakers Confirmed?: Yes

Have you proposed this same symposium to CPDD before?: No

Have you chaired a workshop or symposium at CPDD in the past 3 years?: No

Describe any special scheduling issues (e.g. foreign speaker can come to CPDD for only a limited time)?: N/A

Do you require AV equipment?: Yes

Would you accept a workshop?: No

IsaParentAbstract: 1

Prefix: Dr.

First Name: Yasmin

Last Name: Zakiniaeiz

Degrees: MA MD Ph.D etc:: PhD
Email: yasmin.zakinaeiz@yale.edu

Company Affiliation: Yale University

Mailing Address: 330 Cedar Street

Address 2: Suite LMP85

City: New Haven

State: CT

Zip/Postal: 06519

Country: United States

Phone: 646-981-3355

Membership Year: 2017

Sponsor: Dr. Marc Potenza, PhD

Travel Award: ECI2017, W&G 2018

Research Interests: Behavioral Pharmacology, Neurobiology
Cue-reactivity among cigarette smokers and the importance of the insula from initiation to relapse

Yasmin Zakiniaeiz, Yale University, yasmin.zakiniaeiz@yale.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

Prefix: Dr.
First Name: Yasmin
Last Name: Zakiniaeiz
Degrees: MA MD Ph.D etc.: PhD
Email: yasmin.zakiniaeiz@yale.edu
Company Affiliation: Yale University
Mailing Address: 330 Cedar Street
Address 2: Suite LMP85
City: New Haven
State: CT
Zip/Postal: 06519
Country: United States
Phone: 646-981-3355
Membership Year: 2017
Sponsor: Dr. Marc Potenza, PhD
Travel Award: ECI2017, W&G 2018
Research Interests: Behavioral Pharmacology, Neurobiology
Acute stress alters cued-evoked neural response and potentiates nicotine-seeking among cigarette smokers

Yasmin Zakiniaeiz, Yale University, yasmin.zakiniaeiz@yale.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 100
Prefix: Dr.
First Name: Yasmin
Last Name: Zakiniaeiz
Degrees: MA MD Ph.D etc:: PhD
Email: yasmin.zakiniaeiz@yale.edu
Company Affiliation: Yale University
Mailing Address: 330 Cedar Street
Address 2: Suite LMP85
City: New Haven
State: CT
Zip/Postal: 06519
Country: United States
Phone: 646-981-3355
Membership Year: 2017
Sponsor: Dr. Marc Potenza, PhD
Travel Award: ECI2017, W&G 2018
Research Interests: Behavioral Pharmacology, Neurobiology
Further exploration into the influence of sex and hormones on cigarette smoking cue-reactivity

Yasmin Zakiniaeiz, Yale University, yasmin.zakiniaeiz@yale.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 100
Prefix: Dr.
First Name: Yasmin
Last Name: Zakiniaeiz
Degrees: MA MD Ph.D etc.: PhD
Email: yasmin.zakiniaeiz@yale.edu
Company Affiliation: Yale University
Mailing Address: 330 Cedar Street
Address 2: Suite LMP85
City: New Haven
State: CT
Zip/Postal: 06519
Country: United States
Phone: 646-981-3355
Membership Year: 2017
Sponsor: Dr. Marc Potenza, PhD
Travel Award: ECI2017, W&G 2018
Research Interests: Behavioral Pharmacology, Neurobiology
The central role of smoking cues in reconsolidation-based interventions for cigarette smokers

Yasmin Zakiniaeiz, Yale University, yasmin.zakiniaeiz@yale.edu

Is Speaker a CPDD Member?: No
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

First Name: Yasmin
Last Name: Zakiniaeiz
Degrees: MA MD Ph.D etc:: PhD
Email: yasmin.zakiniaeiz@yale.edu
Company Affiliation: Yale University
Mailing Address: 330 Cedar Street
Address 2: Suite LMP85
City: New Haven
State: CT
Zip/Postal: 06519
Country: United States
Phone: 646-981-3355
Membership Year: 2017
Sponsor: Dr. Marc Potenza, PhD
Travel Award: ECI2017, W&G 2018
Research Interests: Behavioral Pharmacology, Neurobiology
ID: 105
Stress and cue-reactivity: Challenges and potential opportunities

Yasmin Zakiniaeiz, Yale University, yasmin.zakiniaeiz@yale.edu

Is Speaker a CPDD Member?: Yes
Will this individual be the Discussant?: Yes
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: Yes

IsaParentAbstract: 0
ParentAbstract: 100
Prefix: Dr.
First Name: Yasmin
Last Name: Zakiniaeiz
Degrees: MA MD Ph.D etc:: PhD
Email: yasmin.zakiniaeiz@yale.edu
Company Affiliation: Yale University
Mailing Address: 330 Cedar Street
Address 2: Suite LMP85
City: New Haven
State: CT
Zip/Postal: 06519
Country: United States
Phone: 646-981-3355
Membership Year: 2017
Sponsor: Dr. Marc Potenza, PhD
Travel Award: ECI2017, W&G 2018
Research Interests: Behavioral Pharmacology, Neurobiology
Developmental factors contributing to opioid use disorder vulnerability

Da-Yu Wu, National Institute of Drug Abuse, National Institutes of Health, wudy@nida.nih.gov

Chair: Yasmin Hurd

Co-Chair: Junstine Larson

Summary: Evidence suggests that both genes and early environmental factors contribute to the future propensity to develop opioid use disorders (OUD). These factors may include early life (embryonic, fetal or after birth) exposure to opioids and other drugs, genomic predisposition for substance dependence, childhood trauma and maltreatment, and psychosocial adversities. Exactly how these environmental insults interact with genome to alter the developmental trajectory of brain and behavior, and promote the propensity to develop OUD will be discussed at this symposium. Dr. Strathearn will present his studies on long term effects of child maltreatment on risk of substance abuse and dependence. Dr. Andersen will present data on how early life trauma and opiates interact to produce susceptibility to opioid dependence. Dr. Hurd will talk about her research on the effect of embryonic exposure to cannabinoids that heightens adult opioid sensitization and craving. Finally, Dr. Nielsen will discuss how genomic variations and epigenetic regulation that impact brain development and exacerbate vulnerability for OUD.

Key Words: opioids vulnerability developing brain epigenetic

Are all Speakers Confirmed?: Yes

Have you proposed this same symposium to CPDD before?: No

Have you chaired a workshop or symposium at CPDD in the past 3 years?: No

Describe any special scheduling issues (e.g. foreign speaker can come to CPDD for only a limited time)?: None.

Do you require AV equipment?: Yes

Would you accept a workshop?: Yes

IsaParentAbstract: 1

Prefix: Dr.

First Name: Da-Yu

Last Name: Wu

Degrees: MA MD Ph.D etc.: PhD

Email: wudy@nida.nih.gov
CC Email: SELMANEM@NIDA.NIH.GOV

Company Affiliation: National Institute of Drug Abuse, National Institutes of Health

Mailing Address: 6001 Executive Blvd

Address 2: NSC 4265, MSC 9555

City: Bethesda

State: MD

Zip/Postal: 20892

Country: United States

Phone: 301-435-4649

Biography: dyw
ID: 112
Medical devices and substance use disorders: Linking efforts from academia, industry and government. A Town Hall presented by the CPDD academia, industry and academia committee

Marco Pravetoni, University of Minnesota Medical School, prave001@umn.edu

Chair: Marco Pravetoni

Co-Chair: Sean Luo

Summary: This Town Hall offered by the CPDD industry, government, and academia committee focuses on development and approval of medical devices for the treatment of substance use disorders. The Bridge Device has now received FDA labeling for opioid use withdrawal, and FDA has granted approval for 200 devices for pain as well as an app-as-med device for opioid use treatment. The FDA recently held a workshop to discuss regulatory paths for approving devices for the prevention and treatment of opioid use disorder, which can apply to other substance use disorders. This Town Hall will address this topic into a four-part presentation followed by Q&A with the audience, a format proven to be successful at our previous CPDD Townhall from this advisory committee. Part I: Dr. Tendler (Brainsway) discusses use of Transcranial Magnetic Stimulation (TMS) as a treatment for a variety of substance use disorders. Part II: Dr. Miranda (Innovative Health Solutions) discusses the process of developing an FDA-approved device for neuromodulation of peripheral vagal nerve to treat opioid withdrawal. Part III: Dr. Wai (Columbia University) will discuss challenges of developing novel therapeutic devices in academia, and new technologies at the horizon. Part IV: Dr. Jarow (FDA) discusses regulatory guidelines for new devices in the context of substance use disorders or pain management. Dr. Luo (Columbia University) will be the discussant. Collectively, different perspectives from regulators, industry, and academia will encourage a lively debate to enable CPDD’s audience to advance their appreciation of how future medical devices for substance use might be developed.

Key Words: devices, FDA, substance use disorders, regulatory approval, opioid

Are all Speakers Confirmed?: Yes

Have you proposed this same symposium to CPDD before?: No

Have you chaired a workshop or symposium at CPDD in the past 3 years?: Yes

Describe any special scheduling issues (e.g. foreign speaker can come to CPDD for only a limited time)?: Dear Organizers, the CPDD Industry, Academia, Government committee will be happy to accept a Town Hall format, which worked well in previous CPDD meetings. Thank you Marco Pravetoni (Chair)

Do you require AV equipment?: Yes

Would you accept a workshop?: Yes

IsaParentAbstract: 1
Prefix: Dr.
First Name: Marco
Last Name: Pravetoni
Degrees: MA MD Ph.D etc:: Ph.D.
Email: prave001@umn.edu
Company Affiliation: University of Minnesota Medical School
Mailing Address: 701 Park Ave. 55415, S9.303
City: Minneapolis
State: MN
Zip/Postal: 55415
Country: United States
Phone: (612) 232-7017
Fax: (612) 337-7189
Membership Year: 2011
Sponsor: Dr. Paul Pental, M.D. and Philip Portoghese, Ph.D.
Research Interests: Pharmacology, Treatment
The effect of siloed harm reduction organizations on the health of people who misuse opioids in the Ohio Valley

Hannah Cooper, Emory University, hcoope3@emory.edu

Is Speaker a CPDD Member?: No
Will this individual be the Discussant?: No
Are the Registration Fees for this Speaker to be 50% waiver of early bird rate?: No

IsaParentAbstract: 0
ParentAbstract: 58
Prefix: Dr.
First Name: Hannah
Middle Initial: LF
Last Name: Cooper
Degrees: MA MD Ph.D etc:: ScD
Email: hcoope3@emory.edu
Company Affiliation: Emory University
Mailing Address: 1518 Clifton Road NE
City: Atlanta
State: GA
Zip/Postal: 30322
Country: United States
Phone: 3472779640